More than ever, M&A transactions can be subject to detailed antitrust reviews in multiple jurisdictions. This can complicate deal negotiations, extend closing timelines and raise greater ...
Last week, the FTC alleged that a private equity firm undertook a “multi-year anticompetitive scheme” to dominate Texas anesthesiology practices through: (1) “serial” acquisitions...
Last week, the FTC settled a director interlock lawsuit with EQT/Quantum, which is notable for three key reasons: (1) it confirms the FTC’s focus on enforcing the interlocking directora...
Proposed changes to the HSR Form and Instructions would, if adopted, substantially increase the time and cost of compliance for private equity firms. The proposed rules would require mor...
On July 19, 2023, the DOJ and FTC released a draft overhaul of the merger guidelines (the Draft Guidelines). Some portions of the Draft Guidelines are consistent with agency practice fro...
On July 10, 2023, Judge Jacqueline Scott Corley of the U.S. District Court for the Northern District of California denied the FTC’s motion for a preliminary injunction to block Microsof...
The U.S. antitrust authorities have proposed extensive changes to the Hart-Scott-Rodino filing requirements. If implemented, these changes will obligate filing parties to provide substant...
On April 14, a unanimous Supreme Court held that parties can challenge the constitutionality of the FTC’s and SEC’s administrative proceedings in federal court before an agency review...
In 2022, China amended its Anti-Monopoly Law (AML) for the first time in fourteen years. This “New AML” significantly increases penalties for antitrust violations, provides greater f...
On February 3, the DOJ’s Antitrust Division withdrew three “outdated” policy statements. Those statements described certain antitrust safe harbors that companies in the healthcare ...
